Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients

BACKGROUND: Treatment options in older acute myeloid leukaemia (AML) patients include intensive chemotherapy, best supportive care (BSC), and hypomethylating agents. Currently, limited data is available on hypomethylating agents in older AML patients in unselected patient populations. METHODS: To co...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Helm, Lieke H, Scheepers, Ellen RM, Veeger, Nic JGM, Daenen, Simon MGJ, Mulder, André B, van den Berg, Eva, Vellenga, Edo, Huls, Gerwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639930/
https://www.ncbi.nlm.nih.gov/pubmed/23587459
http://dx.doi.org/10.1186/1756-8722-6-29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639930/
https://www.ncbi.nlm.nih.gov/pubmed/23587459
http://dx.doi.org/10.1186/1756-8722-6-29

Ejemplares similares